1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride manufacturers
|
| | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride Basic information |
| Product Name: | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride | | Synonyms: | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride;HA-1077 dihydrochloride,1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride;HA-1077 (hydrochloride);1-(5-Isoquinolinesulphonyl)homopiperazine dihydrochloride salt, Fausidil dihydrochoride salt;HA-1077 dihydrochloride solid, >=98% (HPLC);Isoquinoline, 5-[(hexahydro-1H-1,4-diazepin-1-yl)sulfonyl]-, hydrochloride (1:2) | | CAS: | 203911-27-7 | | MF: | C14H17N3O2S.2ClH.H2O | | MW: | 382.31 | | EINECS: | 200-258-5 | | Product Categories: | Inhibitor | | Mol File: | 203911-27-7.mol |  |
| | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride Chemical Properties |
| density | 1.289 | | RTECS | HM4031166 | | Fp | 260℃ | | storage temp. | Store at -20°C | | solubility | H2O: >10mg/mL | | form | solid | | color | white to off-white | | Water Solubility | Soluble in water and dimethylsulfoxide. |
| Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29339900 |
| | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride Usage And Synthesis |
| Description | Rho-associated kinase (ROCK), an effector of the small GTP-binding protein Rho, plays an important role in various cellular functions including vascular smooth muscle contraction, proliferation, and migration as well as inflammatory cell mobility. HA-1077 is a potent inhibitor of ROCK2 and additionally inhibits protein kinase c-related kinase 2 (PRK2), mitogen- and stress-activated protein kinase (MSK1), and mitogen activated protein kinase-activated protein kinase 1b (MAPKAP-K1b) with IC50 values of 1.9, 4, 5, and 15 μM, respectively. By inhibiting the activity of ROCK, HA-1077 has been shown to reduce blood vessel constriction, decrease pulmonary arterial pressure, inhibit tumor angiogenesis, and improve insulin signaling in various rodent models. While originally marketed for the prevention of cerebral vasospasm in patients with subarachnoid hemorrhage, oral formulations of HA-1077 are used for the treatment of a wide range of cardiovascular diseases including pulmonary arterial hypertension and stable angina. | | Chemical Properties | White fine crystalline powder | | Uses | HA-1077 dihydrochloride has been used:
- to relax cantilevers
- in the functional assessment of isolated coronary arteries
- to investigate the effect of azaindole-1, fasudil on acute hypoxic pulmonary vasoconstriction (HPV)
| | Uses | Fasudil dihydrochloride is used in the inhibition of contractile responses to potassium chloride, phenylephnne (PHE), prostaglandin and hepatic stellate cells spreading. It is also used in the formation of stress fibers and in medicine. | | Biochem/physiol Actions | Novel vasodilator agent which inhibits vascular smooth muscle contraction by acting as an intracellular Ca2+ antagonist. | | in vivo | Fasudil dihydrochloride (10 mg/kg; i.v.; 1 h before operation) exhibits protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury[5].
Fasudil dihydrochloride (50 mg/kg/d; i.p.) inhibits acute and relapsing EAE (experimental autoimmune encephalomyelitis) induced by proteolipid protein PLP p139-151, reduces lymphocytes proliferation, results downregulation of interleukin (IL)-17 and a marked decrease of the IFN-γ/IL-4 ratio[6].
Fasudil dihydrochloride (100 mg/kg/d; p.o.) significantly reduces incidence and pathological examination score of EAE (experimental autoimmune encephalomyelitis) in SJL/J mice, decreases inflammation, demyelination, axonal loss and APP positivein spinal cord in mice[6]. | Animal Model: | Myocardial ischemia and reperfusion in rat (250-300 g)[5] | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection; 1 h before operation | | Result: | Activated the Rho-kinase, JNK, and resulted AIF translocated to the nucleus.
Inhibited Rho-kinase activity, and reduced myocardial infarct size and heart cell apoptosis.
|
| | IC 50 | PKA: 4.58 μM (IC50); PKC: 12.3 μM (IC50); PKG: 1.65 μM (IC50); p160ROCK: 0.33 μM (Ki); ROCK2: 0.158 μM (IC50) |
| | 1-(5-Isoquinolinylsulfonyl)homopiperazine dihydrochloride, Fasudil dihydrochloride Preparation Products And Raw materials |
|